Bronchodilator Drugs - Benelux | Statista Market Forecast

In the Benelux region, the revenue in the Bronchodilator Drugs market is projected to reach US$375.40m in 2024.
This market is expected to show an annual growth rate (CAGR 2024-2029) of 3.41%, resulting in a market volume of US$443.90m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, with US$17.34bn in 2024.
Benelux has seen a surge in demand for bronchodilator drugs due to the high prevalence of respiratory diseases in the region.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Benelux, the market for bronchodilator drugs has been steadily growing in recent years.

Customer preferences: Patients in Benelux prefer bronchodilator drugs that are easy to use and have minimal side effects. They also prefer drugs that provide quick relief from symptoms and have a long-lasting effect. In addition, there is a growing preference for combination drugs that treat both asthma and COPD.

Trends in the market: One of the major trends in the bronchodilator drugs market in Benelux is the increasing use of combination drugs. These drugs are becoming more popular because they offer a more convenient and effective treatment option for patients with both asthma and COPD. Another trend is the growing use of inhalers, which are more effective and have fewer side effects than traditional oral medications.

Local special circumstances: The healthcare system in Benelux is highly advanced and well-funded, which has contributed to the growth of the bronchodilator drugs market. In addition, the region has a high prevalence of respiratory diseases, which has created a large and growing market for these drugs.

Underlying macroeconomic factors: The economic stability and high standard of living in Benelux have also contributed to the growth of the bronchodilator drugs market. With a strong healthcare system and a high level of disposable income, patients in the region are more likely to seek treatment for respiratory diseases and are willing to pay for high-quality drugs. Furthermore, the region's aging population has increased the demand for bronchodilator drugs, as respiratory diseases are more common among older adults.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.